医学
利拉鲁肽
2型糖尿病
脱胶胰岛素
安慰剂
内科学
糖尿病
临床终点
随机对照试验
胰岛素
血压
内分泌学
甘精胰岛素
病理
替代医学
作者
Rui Wang,Shuoming Luo,Zilin Xiao,Zhiguang Zhou
摘要
Abstract Background The efficacy and safety of fixed‐ratio combination insulin degludec/liraglutide (IDegLira) for type 2 diabetes (T2DM) were extensively investigated by the global DUAL trials. However, the evidence on its efficacy and safety in T2DM has not been systematically reviewed. Methods Randomized controlled trials published in English that compared IDegLira with placebo or GLP‐1 agonists or insulin in patients with T2DM were selected up to December 2022. Data on the study characteristics, efficacy and safety outcomes were extracted. We compared the efficacy and safety between “IDegLira versus Insulin,” “IDegLira versus GLP‐1RA,” and “IDegLira versus Placebo”. The risk of potential bias was assessed. Results In terms of glycaemic efficacy, IDegLira reduced levels of glycated haemoglobin (HbA1c; weighted mean differences (WMDs) 0.52%, 95% CI 0.33%–0.71%); fasting blood glucose (0.32 mg/dL, 0.14–0.50 mg/dL), and the nine‐point self‐measured plasma glucose (0.25 mmol/L, 0.25–0.36 mmol/L). Furthermore, IDegLira was generally better in the attainment of HbA1c < 7.0% or ≤6.5%, HbA1c < 7.0% or ≤6.5% without weight gain and/or without severe or blood glucose‐confirmed hypoglycaemic episodes. In non‐glycaemic efficacy aspects, IDegLira decreased systolic blood pressure but elevated heart rate. In terms of safety outcomes, IDegLira did not appear to be associated with a risk of hypoglycaemia (RR 1.23, 0.85–1.78) and nocturnal hypoglycaemia (0.89, 0.52–1.52) occurring when compared with other hypoglycaemic agents or placebo. Conclusions IDegLira improves better glycaemic and non‐glycaemic outcomes without weight gain and/or without severe or blood glucose‐confirmed hypoglycaemic episodes in T2DM. Side effects of IDegLira are mild.
科研通智能强力驱动
Strongly Powered by AbleSci AI